PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33709954-14	2021	CONCLUSION: PPTs are rare sellar masses with quintessential TTF-1 positivity.	Pyridinium p-toluenesulfonate	12-16	NK2 homeobox 1	Homo sapiens	60-65
15936887-9	2005	Injection of alpha,beta-meATP, an agonist of P2X1,3,2/3R, dramatically reduced the bilateral PPTs of both inflamed and non-inflamed TMJs (P<0.01) although beta,gamma-me-l-ATP, a selective agonist of P2X1R, did not.	Pyridinium p-toluenesulfonate	93-97	purinergic receptor P2X 1	Rattus norvegicus	45-49
32995127-3	2020	Herein, porous platinum nanospheres (pPts), incorporated with GOx molecules (PtGs), are synthesized to enable synergistic cancer therapy.	Pyridinium p-toluenesulfonate	37-41	hydroxyacid oxidase 1	Homo sapiens	62-65
31751392-9	2019	Significantly elevated viral load results (>0.3 log copies/ml difference) have been observed with PPTs; however, when manufacturer handling instructions are followed, when plasma is aliquoted into a secondary tube, or when PPTs are centrifuged prior to testing, PPT results only differed from standard EDTA plasma testing using commercially available viral load assays by a range on average of -0.03 to +0.08 log copies/ml across studies.	Pyridinium p-toluenesulfonate	223-227	tachykinin precursor 1	Homo sapiens	98-101
30325737-18	2019	Regression analysis showed that C4a changes after the submaximal exercise significantly predicted the change in PPTs (R2=0.236; p=0.02).	Pyridinium p-toluenesulfonate	112-116	complement C4A (Rodgers blood group)	Homo sapiens	32-35
27603705-5	2017	The beta-endorphin levels positively correlated with PPTs in PCOS group.	Pyridinium p-toluenesulfonate	53-57	proopiomelanocortin	Homo sapiens	4-18
21464942-8	2011	RESULTS: The low, as compared to the high, 5-HTT-expressing group exhibited significantly reduced CPM-mediated pain inhibition for PPTs (p = 0.02) and heat-pain (p = 0.02).	Pyridinium p-toluenesulfonate	131-135	solute carrier family 6 member 4	Homo sapiens	43-48
10422653-11	1999	However, the combination of 5-HT and BKN (10 nmol) produced: (1) significantly higher VAS scores (P < 0.05) compared with all other combinations; (2) significantly longer pain offset (P < 0.05) compared with the combinations of isotonic saline and BKN; (3) significantly lower PPTs at 5, 20, and 40 min post-infusion (P < 0.05) compared with baseline PPT and PPTs after all other combinations.	Pyridinium p-toluenesulfonate	283-287	kininogen 1	Homo sapiens	37-40
15629873-8	2005	PPTs were significantly lower with the Algometer than with PTMs (ANOVA, p<0.01); again these differences were least when testing over muscle.	Pyridinium p-toluenesulfonate	0-4	parathymosin	Homo sapiens	59-63
10640624-14	2000	In addition, PPTs were significantly decreased (P<0.05) after 5-HT+BKN at 5 cm (5 and 20 min) and 10 cm (5 min).	Pyridinium p-toluenesulfonate	13-17	kininogen 1	Homo sapiens	70-73
10422653-11	1999	However, the combination of 5-HT and BKN (10 nmol) produced: (1) significantly higher VAS scores (P < 0.05) compared with all other combinations; (2) significantly longer pain offset (P < 0.05) compared with the combinations of isotonic saline and BKN; (3) significantly lower PPTs at 5, 20, and 40 min post-infusion (P < 0.05) compared with baseline PPT and PPTs after all other combinations.	Pyridinium p-toluenesulfonate	368-372	kininogen 1	Homo sapiens	37-40
35171826-6	2022	Then, the relationships between recovery from AGHD after TSS and clinical, surgical, and hormonal factors, including peak GH level based on PPTs, were evaluated statistically.	Pyridinium p-toluenesulfonate	140-144	growth hormone 1	Homo sapiens	122-124